Banque Pictet & Cie SA Raises Stock Holdings in DexCom, Inc. $DXCM

Banque Pictet & Cie SA boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 58.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 109,823 shares of the medical device company’s stock after purchasing an additional 40,411 shares during the quarter. Banque Pictet & Cie SA’s holdings in DexCom were worth $7,289,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. CVA Family Office LLC increased its stake in DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 147 shares in the last quarter. GAMMA Investing LLC raised its holdings in DexCom by 2.5% in the third quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock worth $474,000 after purchasing an additional 169 shares during the period. IFP Advisors Inc boosted its position in shares of DexCom by 24.7% during the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after purchasing an additional 178 shares in the last quarter. Inspire Investing LLC grew its holdings in shares of DexCom by 6.1% in the 3rd quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company’s stock valued at $211,000 after buying an additional 180 shares during the period. Finally, Personal CFO Solutions LLC grew its holdings in shares of DexCom by 5.0% in the 3rd quarter. Personal CFO Solutions LLC now owns 3,864 shares of the medical device company’s stock valued at $260,000 after buying an additional 185 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $64.85, for a total value of $110,245.00. Following the completion of the transaction, the executive vice president directly owned 112,904 shares in the company, valued at $7,321,824.40. This trade represents a 1.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Robert W. Baird set a $87.00 price objective on DexCom in a research note on Friday, February 13th. Barclays restated an “underweight” rating and issued a $72.00 price target (up from $71.00) on shares of DexCom in a report on Friday, February 13th. Morgan Stanley reaffirmed an “overweight” rating on shares of DexCom in a research report on Monday, January 12th. Piper Sandler reiterated an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Finally, BTIG Research reiterated a “buy” rating and issued a $85.00 price objective on shares of DexCom in a research report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $86.50.

DexCom Stock Down 0.2%

Shares of DXCM stock opened at $62.22 on Friday. The firm’s fifty day moving average price is $69.32 and its two-hundred day moving average price is $67.30. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98. The firm has a market capitalization of $23.95 billion, a P/E ratio of 29.63, a PEG ratio of 1.22 and a beta of 1.55.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. The company had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The company’s quarterly revenue was up 13.1% on a year-over-year basis. During the same period in the prior year, the business posted $0.45 EPS. On average, equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.